1 00:00:00,080 --> 00:00:09,960 Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report, 2 00:00:10,280 --> 00:00:13,440 Speaker 1: your roundup of companies making moves in the stock market, 3 00:00:13,680 --> 00:00:18,560 Speaker 1: harnessing the power of Bloomberg Data. Stockmovers is John Tucker's 4 00:00:18,560 --> 00:00:22,240 Speaker 1: a podcast. John decided to start out where I am John? 5 00:00:22,320 --> 00:00:25,439 Speaker 2: Did my body Mass Index this weekend? Yeah? 6 00:00:25,560 --> 00:00:28,000 Speaker 1: Came over did my BMI? 7 00:00:28,080 --> 00:00:32,959 Speaker 2: As they say, he said with Govy Novo nordis good 8 00:00:33,080 --> 00:00:36,440 Speaker 2: luck with that. Yeah, I mean I know a lot 9 00:00:36,479 --> 00:00:39,159 Speaker 2: of people who take it, but the side effects it 10 00:00:39,320 --> 00:00:42,839 Speaker 2: just you know, can vary from individual to individual. Now 11 00:00:42,880 --> 00:00:46,880 Speaker 2: there's apparently a new use for it. Novo shares advancing 12 00:00:46,920 --> 00:00:51,600 Speaker 2: after the drugmaker's blockbuster weight loss drug WEGV has now 13 00:00:51,640 --> 00:00:56,240 Speaker 2: received US approval to treat a serious form of liver disease. 14 00:00:57,200 --> 00:00:59,480 Speaker 2: The important part of this also is that they beat 15 00:00:59,480 --> 00:01:02,480 Speaker 2: one of their competitors, Eli Lilly to the US market, 16 00:01:03,040 --> 00:01:06,720 Speaker 2: So this particular approval gives Novo a big win in 17 00:01:06,760 --> 00:01:10,240 Speaker 2: the booming market for the GLP one drugs they of course, 18 00:01:10,280 --> 00:01:14,680 Speaker 2: have been popularized for weight loss. The drug makers started 19 00:01:14,720 --> 00:01:17,959 Speaker 2: the year as Europe's most valuable traded company, but it's 20 00:01:18,080 --> 00:01:22,320 Speaker 2: since lost about half of its value as it wrestles 21 00:01:22,360 --> 00:01:26,120 Speaker 2: with fierce competition in the obesity market. So the liver 22 00:01:26,200 --> 00:01:29,280 Speaker 2: clearance marks the second boost for Nova this month, after 23 00:01:29,360 --> 00:01:34,280 Speaker 2: disappointing data from Lily's obesity bill boosted investor hopes about 24 00:01:34,760 --> 00:01:39,119 Speaker 2: Novo's ability to Competegovie was clear for a disease known 25 00:01:39,160 --> 00:01:43,759 Speaker 2: as mash in adults with moderate to advance scar tissue 26 00:01:43,760 --> 00:01:46,880 Speaker 2: in the liver. A mash develops when fat builds up 27 00:01:46,920 --> 00:01:50,440 Speaker 2: in the liver, causing inflammation and potentially leading to more 28 00:01:50,480 --> 00:01:53,960 Speaker 2: serious conditions like cirrhosis and cancer. So Wgovie helps reverse 29 00:01:54,000 --> 00:01:58,160 Speaker 2: the damage to the liver, according to Novo nord Disk. Next, 30 00:01:59,200 --> 00:02:02,960 Speaker 2: let's go to a company called day Force, the ticker 31 00:02:03,040 --> 00:02:08,480 Speaker 2: symbol day so human resources management software provider. It is 32 00:02:08,520 --> 00:02:12,800 Speaker 2: the target of Tomo Bravo, the buyout firm planning to 33 00:02:12,840 --> 00:02:16,360 Speaker 2: take the Minneapolis based company private. This is a deal 34 00:02:16,560 --> 00:02:19,320 Speaker 2: that could be announced as soon as the coming weeks. 35 00:02:19,560 --> 00:02:23,320 Speaker 2: Day four shares they have fallen about the sixty percent 36 00:02:23,400 --> 00:02:26,680 Speaker 2: from their twenty twenty one peak, while the company increased 37 00:02:26,720 --> 00:02:30,040 Speaker 2: revenue more than seventy percent between twenty twenty one and 38 00:02:30,080 --> 00:02:33,639 Speaker 2: twenty twenty four and became more profitable again. This is 39 00:02:33,680 --> 00:02:39,520 Speaker 2: the enterprise software market. They make human resources software. This 40 00:02:39,720 --> 00:02:44,040 Speaker 2: market has had difficulties maintaining momentum after a run up 41 00:02:44,120 --> 00:02:49,560 Speaker 2: during the COVID nineteen lockdowns, and let's wrap up with 42 00:02:49,639 --> 00:02:53,679 Speaker 2: this one. We constantly asked the question Apple, where's its 43 00:02:53,760 --> 00:02:58,120 Speaker 2: mojo going? An interesting take from Mark German. He focuses 44 00:02:58,160 --> 00:03:02,520 Speaker 2: on Apple's Vision Pro headset. It isn't selling well for 45 00:03:02,560 --> 00:03:04,520 Speaker 2: a couple of reasons. First of all, it's thirty five 46 00:03:04,600 --> 00:03:07,360 Speaker 2: hundred dollars price sag, and then there's the lack of 47 00:03:07,400 --> 00:03:11,840 Speaker 2: sufficiently compelling features. There are other issues like a limited 48 00:03:11,919 --> 00:03:16,600 Speaker 2: array of custom applications and the device's weight and cumbersome 49 00:03:16,800 --> 00:03:21,080 Speaker 2: setup process. By all accounts, the device remains an extremely 50 00:03:21,280 --> 00:03:24,960 Speaker 2: niche product. Moreover, the headset doesn't feel like a priority 51 00:03:25,000 --> 00:03:27,960 Speaker 2: for Apple. On the the last earnings call, for instance, 52 00:03:28,280 --> 00:03:31,320 Speaker 2: Tim Cook almost seems surprised when a Wallstreet analyst quiz 53 00:03:31,400 --> 00:03:35,560 Speaker 2: him about the device and also the company's strategy. So 54 00:03:36,040 --> 00:03:38,120 Speaker 2: there you go. Mark Dermott strikes again on it. 55 00:03:39,400 --> 00:03:43,440 Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with 56 00:03:43,520 --> 00:03:46,080 Speaker 1: us throughout the day for the latest roundup of companies 57 00:03:46,160 --> 00:03:49,240 Speaker 1: making news on Wall Street and for the latest market 58 00:03:49,280 --> 00:03:53,720 Speaker 1: moving headlines. Listen to Bloomberg Radio Live. Catch us on YouTube, 59 00:03:53,840 --> 00:03:57,360 Speaker 1: Bloomberg dot com, and on Applecarplay and Android Auto with 60 00:03:57,400 --> 00:04:03,400 Speaker 1: the Bloomberg Business appe